Recombinant Mouse T-cell immunomodulatory protein (Itfg1)

What is the molecular structure of mouse Itfg1 and how does it compare to human ITFG1?

Mouse Itfg1 is a glycoprotein of approximately 96-100 kDa that contains FG-GAP (phenylalanyl-glycyl-glycyl-alanyl-prolyl) repeats, domains critical for protein-protein interactions. Structurally, it appears to be a type I transmembrane protein with an N-terminal extracellular domain coupled to a C-terminal transmembrane and cytoplasmic region . The mouse protein shares remarkable homology with human ITFG1, with 89% amino acid sequence identity over positions 1-566 . Both proteins contain similar functional domains, including an N-terminal signal peptide and C-terminal transmembrane domain flanking multiple N-linked glycosylation sites .

Table 1: Comparison of Mouse Itfg1 and Human ITFG1

What are the primary functions of Itfg1 in the immune system?

Despite its name suggesting T-cell specificity, Itfg1 functions more broadly as an immunomodulatory protein. When recombinant Itfg1 protein is added to human and mouse T cells in vitro, it stimulates secretion of multiple cytokines including IFN-γ, TNF-α, and IL-10 after CD3/CD28-mediated activation . Significantly, in vivo studies demonstrate that Itfg1 exhibits protective effects in mouse models of acute graft-versus-host disease (GVHD) . This suggests that Itfg1 plays an important immunoregulatory role, potentially by modulating T-cell responses and inflammatory processes.

What is the expression pattern of Itfg1 across tissues?

Itfg1 demonstrates a paradoxical expression pattern. While generally described as ubiquitously expressed across tissues, it is notably absent on T cells, B cells, and monocytes , despite its involvement in T-cell biology. This expression profile suggests that Itfg1 may function through intercellular interactions rather than cell-autonomous mechanisms in immune regulation. Researchers should consider this when designing experiments targeting specific cell populations.

How does Itfg1 influence liver regeneration and what mechanisms are involved?

Recent research has identified Itfg1 as a promising target for enhanced liver regeneration and chronic liver disease treatment . Itfg1 functions as a "regeneration break" in the liver, and its knockdown produces remarkable effects:

• Accelerated proliferation and wound healing of both mouse and human hepatocytes in vitro

• Enhanced ability of hepatocytes to repopulate the liver in FAH deficient mice

• Accelerated liver regeneration upon partial hepatectomy in fully repopulated mice

• Attenuation of thioacetamide (TAA) and "Western Diet" induced chronic liver damage

These findings suggest that targeting Itfg1 could be a novel therapeutic approach for enhancing endogenous liver regenerative capacity. Researchers established these effects through comprehensive in vivo functional genetic RNAi screening in the TAA-driven chronic liver disease model, where two independent shRNAs targeting Itfg1 were significantly enriched .

What protein-protein interactions does Itfg1 participate in and what is their functional significance?

Itfg1 engages in several important protein interactions that appear crucial for its biological functions. The interaction between Itfg1 and RUVBL1 has been validated in multiple experimental systems including breast cancer cell lines, where it is implicated in cancer metastasis . Through immunoprecipitation and mass spectrometry approaches, researchers have identified approximately 180 potential Itfg1-interacting proteins in MDA-MB-231 breast cancer cells .

Three notable interactors whose C. elegans orthologs produce similar phenotypes to Itfg1 knockdown include:

• ATP9A/tat-5 (phospholipid translocase)

• NME1/ndk-1 (nucleoside diphosphate kinase)

• ANAPC2/apc-2 (E3 ubiquitin ligase component)

Gene ontology analysis of Itfg1-interacting proteins reveals enrichment in multiple cellular networks, including cell cycle regulation, mitochondrial translation initiation, and DNA repair processes , suggesting diverse functional roles.

How does Itfg1 contribute to cell adhesion and migration during development?

Research in C. elegans has established that the Itfg1 ortholog (LNKN-1) is essential for maintaining tissue integrity during collective cell migration . Loss-of-function analysis of LNKN-1 in C. elegans results in migratory detachment phenotypes, indicating that Itfg1 plays a critical role in cell-cell or cell-matrix adhesion during migration . This function appears conserved, as epitope-tagged ITFG1 localizes to the cell surface of human breast cancer cells , consistent with a role in adhesion.

The involvement of Itfg1 in both cell adhesion and immune modulation represents an intriguing connection between these biological processes that warrants further investigation.

What approaches are available for manipulating Itfg1 expression in experimental models?

Researchers have successfully employed several strategies to modulate Itfg1 expression:

• RNA interference (RNAi): In vivo functional genetic RNAi screens have utilized shRNAs targeting Itfg1, with two independent shRNAs showing significant enrichment in liver disease models .

• CRISPR/Cas9 gene editing: All-in-One lentivector systems containing sgRNAs targeting Itfg1 are available for gene knockout experiments. These typically include sets of three sgRNA targets designed to create frameshift mutations in exonic regions .

Table 2: Experimental Approaches for Itfg1 Manipulation

When designing knockout strategies, researchers should consider targeting early exons to maximize the likelihood of complete functional disruption and carefully validate editing efficiency.

What methods are most reliable for detecting Itfg1 expression and localization?

Several validated approaches for detecting Itfg1 expression and localization have been reported:

• Flow cytometry: K562 human chronic myelogenous leukemia cell line has been successfully stained with anti-human ITFG1 antibodies (both APC-conjugated and unconjugated followed by secondary detection) . This approach is particularly useful for quantifying cell surface expression.

• Subcellular fractionation: This technique has confirmed that ITFG1 primarily localizes to the membrane fraction in MDA-MB-231 cells , providing biochemical evidence for its membrane association.

• Immunostaining: Direct visualization of ITFG1 on the plasma membrane of transfected cells has been achieved through immunofluorescence microscopy .

• Western blot: Anti-ITFG1 antibodies can detect the protein at the expected molecular weight range (75-100 kDa) .

For optimal results in detecting endogenous Itfg1, which may be expressed at low levels in some cell types, researchers should consider using signal amplification techniques and carefully validated antibodies.

What are the optimal conditions for producing functional recombinant mouse Itfg1?

While specific production protocols for mouse recombinant Itfg1 are not detailed in the provided literature, several considerations can be extrapolated from related research:

• Expression system: E. coli has been successfully used to produce recombinant human ITFG1 fragments , but for full-length glycosylated protein, eukaryotic expression systems (mammalian, insect) would likely yield more functionally relevant protein.

• Purification strategy: Recombinant ITFG1 fragments with His-ABP tags have been produced at concentrations of ≥5.0 mg/mL , suggesting affinity purification is effective.

• Storage conditions: Recombinant ITFG1 antibodies are typically stored at -20°C to -70°C for long-term stability, with limited freeze-thaw cycles recommended .

For functional studies, researchers should confirm that recombinant Itfg1 retains its ability to stimulate cytokine production in T cells, as this provides a reliable functional readout.

How can I validate the specificity of Itfg1 antibodies for immunological applications?

To ensure antibody specificity when working with Itfg1:

• Blocking experiments: Human ITFG1 control fragment recombinant protein (aa 284-423) has been used for blocking experiments with corresponding antibodies. For optimal blocking, a 100x molar excess of the protein fragment control is recommended, with pre-incubation of the antibody-protein control fragment mixture for 30 minutes at room temperature .

• Knockout controls: CRISPR/Cas9-mediated knockout cells provide the most stringent negative control for antibody validation.

• Multiple antibody validation: Using antibodies targeting different epitopes of Itfg1 can provide additional confidence in detection specificity.

• Cross-species reactivity: While human ITFG1 antibodies might recognize mouse Itfg1 due to high sequence conservation (89% identity), this should be experimentally validated for each specific antibody.

How should researchers interpret Itfg1 knockdown phenotypes across different model systems?

When interpreting Itfg1 knockdown data, several considerations are essential:

• Cell type specificity: Itfg1 functions appear context-dependent, with distinct roles in hepatocytes, immune cells, and migrating cells . Phenotypic differences between cell types may reflect genuine biological variation rather than experimental inconsistency.

• Acute versus chronic effects: The temporal dynamics of Itfg1 knockdown should be considered, as compensatory mechanisms may emerge over time.

• Cross-species conservation: The similar phenotypes observed upon knockdown of Itfg1 orthologs in different species (e.g., migratory detachment in C. elegans and enhanced liver regeneration in mice) suggest evolutionary conservation of function.

• Interaction network context: Itfg1 functions within a network of protein interactions, and phenotypic effects may depend on the expression of interaction partners in specific experimental systems.

What considerations are important when designing in vivo experiments using recombinant mouse Itfg1?

For in vivo studies with recombinant Itfg1:

• Dosage determination: Titration experiments should be performed to establish dose-response relationships, as different biological effects might require different concentrations.

• Route of administration: Given Itfg1's membrane localization and role in cell-cell interactions, local versus systemic administration may yield different outcomes.

• Half-life and biodistribution: Researchers should determine the pharmacokinetic properties of recombinant Itfg1 to establish appropriate dosing intervals.

• Functional validation: In vivo administration should be validated by measuring expected biological effects, such as cytokine production or protection in GVHD models .

• NIH Guidelines compliance: As work with recombinant proteins falls under NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, appropriate institutional approvals should be obtained .

How can findings from mouse Itfg1 studies be translated to human applications?

Translating mouse Itfg1 findings to human applications is supported by several factors:

• High sequence conservation: The 89% amino acid identity between mouse and human proteins suggests functional conservation .

• Conserved cellular functions: Both mouse and human Itfg1 demonstrate similar effects in hepatocyte proliferation and T-cell cytokine production .

• Cross-species validation: Key findings have been validated in both mouse and human experimental systems, such as the enhanced regenerative capacity upon Itfg1 knockdown in both mouse and human hepatocytes .

• Disease relevance: The protective effects of Itfg1 in mouse GVHD models and its role in liver regeneration suggest potential therapeutic applications that could be developed for human conditions .

What are the most promising therapeutic applications for targeting Itfg1?

Based on current research, several therapeutic applications merit further investigation:

• Liver regeneration enhancement: Itfg1 inhibition represents a promising strategy for enhancing endogenous liver regenerative capacity in patients with chronic liver disease .

• GVHD prevention: The protective effects of Itfg1 in mouse GVHD models suggest potential applications in mitigating complications of hematopoietic stem cell transplantation .

• Cancer metastasis: The interaction between Itfg1 and RUVBL1 and its implication in breast cancer metastasis suggests Itfg1 as a potential target for anti-metastatic therapies .

What technical advances would facilitate more comprehensive studies of Itfg1 function?

Several technological developments would advance Itfg1 research:

• Domain-specific antibodies: Development of antibodies targeting specific functional domains of Itfg1 would enable more precise inhibition studies.

• Tissue-specific conditional knockout models: These would allow temporal and spatial control of Itfg1 deletion to dissect its role in specific physiological contexts.

• Structure-function analysis: Determination of the three-dimensional structure of Itfg1 would facilitate rational design of inhibitors or mimetics.

• Systems biology approaches: Integration of proteomics, transcriptomics, and metabolomics data would provide a more comprehensive understanding of Itfg1's role in cellular networks.

What aspects of Itfg1 biology remain poorly understood?

Despite significant advances, several knowledge gaps remain:

• Transcriptional regulation: The mechanisms controlling Itfg1 expression in different tissues and disease states are not well characterized.

• Post-translational modifications: The functional impact of glycosylation and other potential modifications on Itfg1 activity requires further investigation.

• Signaling pathways: The downstream signaling events triggered by Itfg1 engagement remain to be fully elucidated.

• Developmental roles: The function of Itfg1 during embryonic and postnatal development has not been comprehensively studied.

• Evolutionary conservation: While structural conservation is established, functional conservation across diverse species requires further validation.